NCT03529110
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with spinal cord compression or active central nervous system (CNS) metastases, defined as untreated and symptomatic, or requiring therapy
https://ClinicalTrials.gov/show/NCT03529110